Sinovac’s H1N1 Vaccine Passes Experts Evaluation

Sinovac has reported that Sinovac’s H1N1 vaccine has passed the experts evaluation by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license within this week.

Reportedly, on August 30 and 31, 2009, SFDA had held an experts evaluation conference focused on A/H1N1 vaccines to evaluate Sinovac’s H1N1 vaccine, which has recently completed a clinical trial.

The company said that the result of the experts evaluation conference will be submitted to SFDA on September 1, 2009, which will be the primary opinion for SFDA to issue the production license.

Sinovac has submitted the H1N1 split influenza vaccine without adjuvant for registration approval, which is applicable to all people from 3 to 60 years old. The dosage is 15ug/0.5ml/dose.

Weidong Yin, chairman, president and CEO of Sinovac, said: We are very excited to see that our H1N1 vaccine has passed the experts evaluation conference organized by SFDA. The evaluation result will be the important opinion for SFDA to issue the production license. We expect to obtain the production license within one week. With this approval, we can continue to fulfill our mission to provide top-quality vaccines to prevent and control the spreading of H1N1 virus not only in China, but worldwide.